Publications (by date)

Vanden Borre P, McFadden DG, Gunda V, Sadow PM, Varmeh S, Bernasconi MJ, Jacks T, Parangi S. 2013. The Next Generation of Orthotopic Thyroid Cancer Models: Immunocompetent Orthotopic Mouse Models of BRAF^V600E-Positive Papillary and Anaplastic Thyroid Carcinoma. Thyroid. [Epub ahead of print].

Morandell S, Reinhardt HC, Cannell IG, Kim JS, Ruf DM, Mitra T, Couvillon AD, Jacks T, Yaffe MB. 2013. A Reversible Gene-Targeting Strategy Identifies Synthetic Lethal Interactions between MK2 and p53 in the DNA Damage Response In Vivo. Cell Rep. 27;5(4):868-77.

Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, Burga LN, Xie J, Jurczak MJ, DePinho RA, Clish CB, Jacks T, Kibbey RG, Wulf GM, Di Vizio D, Mills GB, Cantley LC, Vander Heiden MG. 2013. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell. 10;155(2):397-409.

Li CM, Chen G, Dayton TL, Kim-Kiselak C, Hoersch S, Whittaker CA, Bronson RT, Beer DG, Winslow MM, Jacks T. 2013. Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinoma. Genes Dev. 27(14):1557-67.

Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM, Chen G, Price S, Lu W, Teng X, Snyder E, Santanam U, Dipaola RS, Jacks T, Rabinowitz JD, White E. 2013. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev. 27(13):1447-61. PDF

Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, Chen SC, Nakitandwe J, Downing J, Jacks T, Le Beau MM, Shannon K. 2013. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov. 3(9):993-1001.

Curry NL, Mino-Kenudson M, Oliver TG, Yilmaz OH, Yilmaz VO, Moon JY, Jacks T, Sabatini DM, Kalaany NY. 2013. Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction. Cancer Discov. 3(8):908-21.

Physical Sciences - Oncology Centers Network, Agus DB, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, Damania D, Davies PC, Decuzzi P, Dickinson L, Estevez-Salmeron L, Estrella V, Ferrari M, Fischbach C, Foo J, Fraley SI, Frantz C, Fuhrmann A, Gascard P, Gatenby RA, Geng Y, Gerecht S, Gillies RJ, Godin B, Grady WM, Greenfield A, Hemphill C, Hempstead BL, Hielscher A, Hillis WD, Holland EC, Ibrahim-Hashim A, Jacks T, Johnson RH, Joo A, Katz JE, Kelbauskas L, Kesselman C, King MR, Konstantopoulos K, Kraning-Rush CM, Kuhn P, Kung K, Kwee B, Lakins JN, Lambert G, Liao D, Licht JD, Liphardt JT, Liu L, Lloyd MC, Lyubimova A, Mallick P, Marko J, McCarty OJ, Meldrum DR, Michor F, Mumenthaler SM, Nandakumar V, O'Halloran TV, Oh S, Pasqualini R, Paszek MJ, Philips KG, Poultney CS, Rana K, Reinhart-King CA, Ros R, Semenza GL, Senechal P, Shuler ML, Srinivasan S, Staunton JR, Stypula Y, Subramanian H, Tlsty TD, Tormoen GW, Tseng Y, van Oudenaarden A, Verbridge SS, Wan JC, Weaver VM, Widom J, Will C, Wirtz D, Wojtkowiak J, Wu PH. 2013. A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep. 3:1449. PDF

Byun S, Son S, Amodei D, Cermak N, Shaw J, Kang JH, Hecht VC, Winslow MM, Jacks T, Mallick P, Manalis SR. 2013. Characterizing deformability and surface friction of cancer cells. Proc Natl Acad Sci U S A. 7;110(19):7580-5. PDF

Snyder EL, Watanabe H, Magendantz M, Hoersch S, Chen TA, Wang DG, Crowley D, Whittaker CA, Meyerson M, Kimura S, Jacks T. 2013. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell. 50(2):185-99. PDF

Joshi NS, Jacks T. 2013. Immunology. Guilty by association. Science. 8;339(6124):1160-1.

DuPage M, Jacks T. 2013. Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr Opin Immunol. 25(2):192-9.

Watanabe H, Francis JM, Woo MS, Etemad B, Lin W, Fries DF, Peng S, Snyder EL, Tata PR, Izzo F, Schinzel AC, Cho J, Hammerman PS, Verhaak RG, Hahn WC, Rajagopal J, Jacks T, Meyerson M. 2013. Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes Dev.15;27(2):197-210. PDF

Reticker-Flynn NE, Malta DF, Winslow MM, Lamar JM, Xu MJ, Underhill GH, Hynes RO, Jacks TE, Bhatia SN. 2012. A combinatorial extracellular matrix platform identifies cell-extracellular matrix interactions that correlate with metastasis. Nat Commun. 2012;3:1122. PDF

Ravi A, Gurtan AM, Kumar MS, Bhutkar A, Chin C, Lu V, Lees JA, Jacks T, Sharp PA. 2012. Proliferation and Tumorigenesis of a Murine Sarcoma Cell Line in the Absence of DICER1. Cancer Cell, 21(6):848-855. PDF

Farago AF, Snyder EL, Jacks T. 2012.SnapShot: Lung cancer models. Cell, 149(1):246-246.

DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. 2012. Expression of tumour-specific antigens underlies cancer immunoediting. Nature, 482(7385):405-409. PDF

Itzkovitz S, Blat IC, Jacks T, Clevers H, van Oudenaarden A. 2012. Optimality in the development of intestinal crypts. Cell, 148(3):608-619.

Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG. 2011. Treating metastatic cancer with nanotechnology. Nat Rev Cancer, Dec 23;12(1):39-50.

Itzkovitz S, Lyubimova A, Blat IC, Maynard M, van Es J, Lees J, Jacks T, Clevers H, van Oudenaarden A. 2011. Single-molecule transcript counting of stem-cell markers in the mouse intestine. Nat Cell Biol. 14(1):106-114. PMCID: PMC3292866.

Oliver TG, Meylan E, Chang GP, Xue W, Burke JR, Humpton TJ, Hubbard D, Bhutkar A, Jacks T. 2011. Caspase-2-Mediated Cleavage of Mdm2 Creates a p53-Induced Positive Feedback Loop. Molecular Cell, 43(1):57-71. PMCID: PMC3160283.

Xue W, Meylan E, Oliver TG, Feldser DM, Winslow MM, Bronson R, Jacks T. 2011. Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. Cancer Discovery, 1(3):236-47. PMCID: PMC3160630

Dooley AL, Winslow MM, Chiang DY, Banerji S, Stransky N, Dayton TL, Snyder EL, Senna S, Whittaker CA, Bronson RT, Crowley D, Barretina J, Garraway L, Meyerson M, Jacks T. 2011. Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev., 25(14):1470-1475. PMCID: PMC3143937.

Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, Hubbard DD, DuPage M, Whittaker CA, Hoersch S, Yoon S, Crowley D, Bronson RT, Chiang DY, Meyerson M, and Jacks T. 2011. Suppression of Lung Adenocarcinoma Progression by Nkx2-1. Nature, 473(7345):101-104. PMCID: PMC3088778.

Shaw AT, Winslow MM, Magendantz M, Ouyang C, Dowdle J, Subramanian A, Lewis TA, Maglathin RL, Tolliday N, Jacks T. 2011. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A, 08(21):8773-8778. PMCID: PMC3102385.

Young NP, Crowley D and Jacks T. 2011. Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. Cancer Research, 71(11):4040-4047. PMCID: PMC3160277.

DuPage M, Cheung A, Mazumdar , Winslow MM, Bronson R, Schmidt LM, Crowley D, Chen J, and Jacks T. 2011. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell, 19(1):72-85. PMCID: PMC3069809.

Kumar MS, Narla A, Nonami A, Mullally A, Dimitrova N, Ball B, Randall McAuley J, Poveromo L, Kutok JL, Galili N, Raza A, Attar E, Gilliland DG, Jacks T, Ebert BL. 2011. Coordinate loss of a microRNA and protein coding gene cooperate in the pathogenesis of 5q- syndrome. Blood, in press. PMC in process.

To MD, Quigley D, Mao JH, Del Rosario R, Hsu J, Hodgson JG, Jacks T, Balmain A. 2011. Progressive genomic instability in the FVB/KrasLA2 mouse model of lung cancer. Mol Cancer Res, in press. PMC in process.

Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K. 2011. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood, 117(6):2022-32. PMCID: PMC3056645

Cellurale C, Sabio G, Kennedy NJ, Das M, Barlow M, Sandy P, Jacks T, Davis RJ. 2011. Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation. Mol Cell Biol., 31(7):1565-76. PMCID: PMC3135291

Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, Sanchez-Rivera FJ, Resnick R, Bronson R, Hemann MT, and Jacks T. 2010. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature, 468 (7323):572-575. PMCID: PMC3003305.

Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, Cheng M, Subramanian A, Mu D, Powers S, Crowley D, Bronson RT, Whittaker CA, Bhutkar A, Lippard SJ, Golub T, Thomale J, Jacks T, Sweet-Cordero EA. 2010. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes and Development, 24(8):837-852. PMCID: PMC2854397

Young NP, Jacks T. 2010. Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. Proc Natl Acad Sci U S A., 107(22):10184-10189. PMCID: PMC2890471

Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, Walker GC, Hemann MT. 2010. Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proc Natl Acad Sci U S A, 107(48):20786-20791. PMCID: PMC2996428

Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, Khalil AM, Zuk O, Amit I, Rabani M, Attardi LD, Regev A, Lander ES, Jacks T, Rinn JL. 2010. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell, 142(3):409-419. PMCID: PMC2956184

Mazumdar J, Hickey MM, Pant DK, Durham AC, Sweet-Cordero A, Vachani A, Jacks T, Chodosh LA, Kissil JL, Simon MC, Keith B. 2010. HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A., 107(32):14182-14187. PMCID: PMC2922515

Lazzara MJ, Lane K, Chan R, Jasper PJ, Yaffe MB, Sorger PK, Jacks T, Neel BG, Lauffenburger DA. 2010. IMPAIRED SHP2-MEDIATED ERK ACTIVATION CONTRIBUTES TO GEFITINIB SENSITIVITY OF LUNG CANCER CELLS WITH EGFR-ACTIVATING MUTATIONS. Cancer Research, 70(9):3843-3850. PMCID: PMC2897160

Kirsch DG, Santiago PM, di Tomasso E, Sullivan JM, Hou WS, Dayton T, Jeffords LB, Sodha P, Mercer K, Cohen R, Takeuchi O, Korsmeyer SJ, Bronson R, Kim CF, Haigis KM, Jain RK, Jacks T. 2010. p53 Controls Radiation-induced Gastrointestinal Syndrome in Mice Independent of Apoptosis. Science, 327(5965):593-596. PMCID: PMC2897160

Cheung AF, Carter AM, Kostova KK, Woodruff JF, Crowley D, Bronson RT, Haigis KM, Jacks T. 2010. Complete deletion of Apc results in severe polyposis in mice. Oncogene, 29(12):1857-1864. PMCID: PMC2990498

Zhou Y, Rideout WM 3rd, Zi T, Bressel A, Reddypalli S, Rancourt R, Woo JK, Horner JW, Chin L, Chiu MI, Bosenberg M, Jacks T, Clark SC, Depinho RA, Robinson MO, Heyer J. 2010. Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat Biotechnology, 28(1):71-78.

Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T. 2009. Requirement for NF-kB signaling in a mouse model of lung adenocarcinoma. Nature, 462(7269):104-107. PMCID: PMC2780341

Kirsch DG, Grimm J, Guimaraes AR, Wojtkiewicz GR, Perez BA, Santiago PM, Anthony NK, Forbes T, Doppke K, Weissleder R, Jacks T. 2009. Imaging Primary Lung Cancers in Mice to Study Radiation Biology.  International Journal of Radiation Oncology, Biology, Physics, 76(4):973-977. PMCID: PMC2847457.

Kumar MS, P RE, Chen CY, esterLane K, Chin C, Lu J, Kirsch DG, Golub TR, Jacks T . 2009. Dicer1 functions as a haploinsufficient tumor suppressor. Genes and Development, 23 (23), 2700-2705. PMCID: PMC2788328

Gidekel Friedlander SY, Chu GC, Snyder EL, Girnius N, Dibelius G, Crowley D, Vasile E, DePinho RA, Jacks T. 2009. Context-dependent transformation of adult pancreatic cells by oncogenic K-ras. Cancer Cell, 16(5):379-389. PMCID: PMC3048064

Mito JK, Riedel RF, Dodd L, Lahat G, Lazar AJ, Dodd RD, Stangenberg L, Eward WC, Hornicek FJ, Yoon SS, Brigman BE, Jacks T, Lev D, Mukherjee S, Kirsch DG. 2009. Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS One, 4(11):e8075. PMCID: PMC2779485

Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Fröhling S, Chan EM, Sos ML, Michel K, Mermel C, Silver SJ, Weir BA, Reiling JH, Sheng Q, Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S, Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES, Mesirov JP, Root DE, Gilliland DG, Jacks T, Hahn WC. 2009. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature, 462(7269):108-112. PMCID: PMC2783335

Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA. 2009. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell, 16(1):21-32. PMCID: PMC2752826

Yoon SS, Stangenberg L, Lee YJ, Rothrock C, Dreyfuss JM, Baek KH, Waterman PR, Nielsen GP, Weissleder R, Mahmood U, Park PJ, Jacks T, Dodd RD, Fisher CJ, Ryeom S, Kirsch DG. 2009. Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma. Int J Radiat Oncol Biol Phys, 74(4):1207-1216. PMCID: PMC2733223

Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Döhner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC, Gilliland DG. 2009. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell, 137(5):821-834.

Dupage M*, Dooley AL*, Jacks T. 2009. Conditional mouse lung tumor models using adenoviral or lentiviral delivery of Cre recombinase. Nature protocols, 4(7): 1064-1072. PMCID: PMC2757265

Lin YL, Sengupta S, Gurdziel K, Bell GW, Jacks T, Flores ER. 2009. p63 and p73 transcriptionally regulate genes involved in DNA repair.. PLoS Genet. 2009 Oct;5(10):e1000680. PMCID: PMC2752189

Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, Cabili MN, Jaenisch R, Mikkelsen TS, Jacks T, Hacohen N, Bernstein BE, Kellis M, Regev A, Rinn JL, Lander ES. 2009. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature, 458(7235), 223-227. PMCID: PMC2754849

Cheung AF, Dupage MJP, Dong HK, Chen J, Jacks T. 2008. Regulated expression of a tumor-associated antigen reveals multiple levels of T cell tolerance in a mouse model of lung cancer. Cancer Research, 68(22):9459-9468. PMCID: PMC2597052

Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, Liu A, Miu K, Watnick RS, Reinhardt F, McAllister SS, Jacks T, Weinberg RA. 2008. Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell, 134, 62-73. PMC in progress

Ventura, A., Young, A., Winslow, M., Lintault, L., Meissner, A., Erkeland, S., Newman, J., Bronson, R., Crowley, D., Stone, J., Jaenisch, R., Sharp, P., Jacks T. 2008. Targeted deletion reveals essential and overlapping functions of the miR-17~92 family of miRNA clusters. Cell, 132, 875-886. PMCID:PMC2323338

Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, and Jacks T. 2008. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc.Natl.Acad.Sci, 105, 3903-3908. PMCID: PMC2268826

Nolen-Walston RD, Kim CF, Mazan MR, Ingenito EP, Gruntman AM, Tsai L, Boston R, Woolfenden AE, Jacks T, Hoffman AM. 2008. Cellular kinetics and modeling of bronchioalveolar stem cell response during lung regeneration. Am J Physiol Lung Cell Mol Physiol, 294(6): L1158-65. PMCID:PMC2593913

Zhang Q, Menon R, Deutsch EW, Pitteri SJ, Faca VM, Wang H, Newcomb LF, Depinho RA, Bardeesy N, Dinulescu D, Hung KE, Kucherlapati R, Jacks T, Politi K, Aebersold R, Omenn GS, States DJ, Hanash SM. 2008. A mouse plasma peptide atlas as a resource for disease proteomics. Genome Biol, 9(6):R93. PMCID:PMC2481425

Haigis, K.M., Kendall, K.R., Wang Y., Cheung, A, Haigis, M.C, Glickman J.N., Niwa-Kawakita, M., Sweet-Cordero, A., Sebolt-Leopold J., Shannon, K.M., Settleman J., Giovannini M., and Jacks T. 2008. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nature Genetics,40, 600-608. PMCID:PMC2410301

Kissil JL, Walmsley MJ, Hanlon L, Haigis KM, Bender Kim CF, Sweet-Cordero A, Eckman MS, Tuveson DA, Capobianco AJ, Tybulewicz VL, Jacks T. 2007. Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Research, 67(17):8089-8094.

Pandey J, Umphress S, Kang Y, Angdisen J, Naumova A, Mercer K, Jacks T, Jakowlew SB. 2007. Modulation of tumor induction and progression of oncogenic K-ras positive tumors in the presence of TGF-{beta}1 haploinsufficiency. Carcinogenesis, 28, 2589-2596

Kirsch DG, Dinulescu DM, Miller JB, Grimm J, Santiago PM, Young NP, Nielsen GP, Quade BJ, Chaber CJ, Schultz CP, Takeuchi O, Bronson RT, Crowley D, Korsmeyer SJ, Yoon SS, Hornicek FJ, Weissleder R, Jacks T. 2007. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nature Medicine,13(8):992-997.

Wijnhoven SW, Speksnijder EN, Liu X, Zwart E, vanOostrom CT, Beems RB, Hoogervorst EM, Schaap MM, Attardi LD, Jacks T, van Steeg H, Jonkers J, de Vries A. 2007. Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. Cancer Research, 67(10):4648-4656.

Kumar MS, Lu j, Mercer KL, Golub, TR and Jacks T. 2007. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nature Genetics,39(5):673-677.

Shaw AT, Meissner A, Dowdle JA, Crowley D, Magendantz M, Ouyang C, Parisi T, Rajagopal J, Blank LJ, Bronson RT, Stone JR, Tuveson DA, Jaenisch, R, and Jacks, T. 2007. Sprouty-2 Regulates Oncogenic K-ras in Lung Development and Tumorigenesis. Genes & Development, 21(6):694-707.

McLaughlin ME, Kruger GM, Slocum KL, Crowley D, Michaud NA, Huang J, Magendantz M, and Jacks T. 2007. The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion. PNAS,104(9):3261-3266.

Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R and Jacks T. 2007. Restoration of p53 function leads to tumor regression in vivo. Nature 445, 661-665

See also Comment by Sharpless and DePinho, Nature 445, 606-607.

Zhang J, Liu Y, Beard C, Tuveson DA, Jaenisch R, Jacks TE, Lodish HF. 2007. Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways. Blood 109(12):5238-5241.

Macpherson D, Conkrite K, Tam M, Mukai S, Mu D, and Jacks T. 2007. Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification. EMBO J, 26, 784 - 794.

Keller JW, Haigis KM, Franklin JL, Whitehead RH, Jacks T, Coffey RJ. 2006.Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS: gelsolin complex. Oncogene, 26(21):3051-3059.

Charest A, Wilker EW, McLaughlin ME, Lane K, Gowda R, Coven S, McMahon K, Kovach S, Feng Y, Yaffe MB, Jacks T, Housman D.2006.ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res., 66(15):7473-7481.

To MD, Perez-Losada J, Mao JH, Hsu J, Jacks T, Balmain A.2006.A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2(LA2) mice. Nature Genetics, 38(8):926-930.

Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K.2006.Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood, 108(6):2041-2044.

Daikoku T, Tranguch S, Trofimova IN, Dinulescu DM, Jacks T, Nikitin AY, Connolly DC, Dey SK. 2006.Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Research, 66(5):2527-2531.

Tuveson DA, Zhu L, Gopinathan A,Willis NA, Kachatrian L,Grochow R, Pin CL, Mitin NY, Taparowsky EJ,
Gimotty PA, Hruban RH, Jacks T, Konieczny SF. 2006.Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma. Cancer Research, 66(1):242-247.

Sweet-Cordero A, Tseng GC, You H, Douglass M, Huey B, Albertson D, Jacks T. 2006.Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes Chromosomes Cancer, 45(4):338-48.

Haigis K, Sage J, Glickman J, Shafer S, Jacks T. 2005. The related retinoblastoma (pRb) and p130 proteins cooperate to regulate homeostasis in the intestinal epithelium. J Biol Chem., 281(1):638-47

Chao RC, Pyzel U, Fridlyand J, Kuo YM, Teel L, Haaga J, Borowsky A, Horvai A, Kogan SC, Bonifas J, Huey B, Jacks TE, Albertson DG, Shannon KM. 2005. Therapy-induced malignant neoplasms in Nf1 mutant mice . Cancer Cell, 4:337-348.

Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, Jacks T. 2005. The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer . Cancer Research, 65(22)10280-10287.

Grimm J, Kirsch DG, Windsor SD, Kim CF, Santiago PM, Ntziachristos V, Jacks T, Weissleder R.. 2005. Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. PNAS, 102(40):14404-14409

Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, van den Berg J, Jacks T, van Steeg H, de Vries A. 2005. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development.Cancer Res, 65(18):8166-8173.

Sandy P, Ventura A, Jacks T. 2005. Mammalian RNAi: a practical guide.Biotechniques, 39(2):215-224.

Kuns R, Kissil JL, Newsham IF, Jacks T, Gutmann DH, Sherman LS. 2005. Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation. Oncogene, 24(43):6502-15

Shaw AT, Kirsch DG, Jacks T. 2005. Future of early detection of lung cancer: the role of mouse models. . Clin Cancer Res. 11(13 Pt 2):4999s-5003s

Kim CF ,Jackson EL ,Woolfenden AE ,Lawrence S ,Babar I ,Vogel S ,Crowley D ,Bronson RT ,Jacks T .2005. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell. 121(6):823-835.

See also: "Stem Cells for Lung Cancer?" by Anton Berns, Cell,121(6), 811-813

Lu J ,Getz G ,Miska EA ,Alvarez-Saavedra E ,Lamb J ,Peck D ,Sweet-Cordero A ,Ebert BL ,Mak RH ,Ferrando AA ,Downing JR ,Jacks T ,Horvitz HR ,Golub TR .2005. MicroRNA expression profiles classify human cancers. Nature. 435(7043):834-838.

Bono P ,Cordero E ,Johnson K ,Borowsky M ,Ramesh V ,Jacks T ,Hynes RO . 2005. Layilin, a cell surface hyaluronan receptor, interacts with merlin and radixin. Exp Cell Res. 2005 [Epub ahead of print]

Hoogervorst EM ,Bruins W ,Zwart E ,van Oostrom CT ,van den Aardweg GJ ,Beems RB ,van den Berg J ,Jacks T ,van Steeg H ,de Vries A . 2005. Lack of p53 Ser389 phosphorylation predisposes mice to develop 2-acetylaminofluorene-induced bladder tumors but not ionizing radiation-induced lymphomas. . Cancer Res. 65(9):3610-3616.

Elsa R. Flores, Shomit Sengupta, John B. Miller, Jamie Newman, Roderick Bronson, Denise Crowley, Annie Yang, Frank McKeon, Tyler Jacks. 2005. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell, (4):363-373

Alejandro Sweet-Cordero, Sayan Mukherjee, Aravind Subramanian, Han You, Jeff
Roix, Christine Ladd, Jill Mesirov, Todd R. Golub, Tyler Jacks. 2005. An oncogenic Kras expression signature identified by cross-species gene expression analysis. Nature Genetics, 37 (1), 48-55

Gene expression data available here

See also article by Thomas G Graeber & Charles L Sawyers: "Cross-species comparisons of cancer signaling", Nature Genetics, 37 (1), 7 - 8 (2005)

Daniela M. Dinulescu, Tan A. Ince, Bradley J. Quade, Sarah A. Shafer, Denise Crowley, Tyler Jacks. 2005. Role of K-ras and Pten in the Development of Mouse Models of Endometriosis and Endometrioid Ovarian Cancer. Nature Medicine, 11 (1), 63 - 70.

See also article by Martin M Matzuk: "Gynecologic diseases get their genes", Nature Medicine, 11 (1), 24-26 (2005)

Kenneth P. Olive, David A. Tuveson, Zachary C. Ruhe, Bob Yin, Nicholas A. Willis, Roderick T. Bronson, Denise Crowley, Tyler Jacks. 2004. Mutant p53 Gain-of-Function in Two Mouse Models of Li-Fraumeni Syndrome. Cell,119 (6), 847-860.

See also review in: Cell, 120 (1) 7-10 (2005).

Spike BT, Dirlam A, Dibling BC, Marvin J, Williams BO, Jacks T, Macleod KF. 2004. The Rb tumor suppressor is required for stress erythropoiesis. EMBO J., 23(21):4319-4329.

Bruins W, Zwart E, Attardi LD, Iwakuma T, Hoogervorst EM, Beems RB, Miranda B, van Oostrom CT, van den Berg J, van den Aardweg GJ, Lozano G, van Steeg H, Jacks T, de Vries A. 2004. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol. 20:8884-8894.

Iwakuma T, Parant JM, Fasulo M, Zwart E, Jacks T, De Vries A, Lozano G. 2004. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene, 23(46):7644-7650.

MacPherson D, Kim J, Kim T, Rhee BK, Van Oostrom CT, DiTullio RA, Venere M, Halazonetis TD, Bronson R, De Vries A, Fleming M, Jacks T. 2004. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J. 23(18):3689-3699.

Reilly KM, Tuskan RG, Christy E, Loisel DA, Ledger J, Bronson RT, Smith CD, Tsang S, Munroe DJ, Jacks T. 2004. Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. PNAS U S A. 101(35):13008-13013.

Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs L, Jaenisch R, Jacks T. 2004. Cre-lox-regulated conditional RNA interference from transgenes. PNAS (101):10380-10385.

MacPherson D, Sage J, Kim T, Ho D, McLaughlin ME, Jacks T. 2004. Cell type-specific effects of Rb deletion in the murine retina. . Genes Dev.18(14):1681-1694.

Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, Hingorani SR, Zaks T, King C, Jacobetz MA, Wang L, Bronson RT, Orkin SH, DePinho RA, Jacks T. 2004. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (4):375-387.

Mayhew CN, Perkin LM, Zhang X, Sage J, Jacks T, Knudsen ES. 2004. Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents. Oncogene 23(23):4107-4120.

Nikitin AY, Alcaraz A, Anver MR, Bronson RT, Cardiff RD, Dixon D, Fraire AE, Gabrielson EW, Gunning WT, Haines DC, Kaufman MH, Linnoila RI, Maronpot RR, Rabson AS, Reddick RL, Rehm S, Rozengurt N, Schuller HM, Shmidt EN, Travis WD, Ward JM, Jacks T. 2004. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res. 64(7):2307-2316.

Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, Johnson L, Akashi K, Tuveson DA, Jacks T, Gilliland DG. 2004. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 113(4):528-538.

Attardi LD, de Vries A, Jacks T. 2004. Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. Oncogene 23(4):973-80.

Bosco EE, Mayhew CN, Hennigan RF, Sage J, Jacks T, Knudsen ES.2004. RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. Nucleic Acids Res. 2(1):25-34.

Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM. 2004. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A. 101(2):597-602.

Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA. 2003. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 4(6):437-50

Reczek EE, Flores ER, Tsay AS, Attardi LD, Jacks T. 2003 Multiple response elements and differential p53 binding control Perp expression during apoptosis. Mol Cancer Res.1(14):1048-1057.

Karlseder J, Kachatrian L, Takai H, Mercer K, Hingorani S, Jacks T, de Lange T.2003 Targeted deletion reveals an essential function for the telomere length regulator Trf1. Mol Cell Biol.23(18):6533-6541.

Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T. 2003. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell. 2003 Oct;12(4):841-9.

Ihrie RA, Reczek E, Horner JS, Khachatrian L, Sage J, Jacks T, Attardi LD 2003. Perp Is a Mediator of p53-Dependent Apoptosis in Diverse Cell Types.Curr Biol. Nov 11;13(22):1985-90.

Minna JD, Kurie JM, Jacks T. 2003. A big step in the study of small cell lung cancer.Cancer Cell. Sep;4(3):163-6.

Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T. 2003. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature. Jul 10;424(6945):223-8.

McLaughlin ME, Jacks T. 2003. Progesterone receptor expression in neurofibromas. Cancer Res. Feb 15;63(4):752-5.

Cichowski K, Santiago S, Jardim M, Johnson BW, Jacks T. 2003. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor.Genes Dev. Feb 15;17(4):449-54.

MacPherson D, Sage J, Crowley D, Trumpp A, Bronson RT, Jacks T. 2003. Conditional mutation of Rb causes cell cycle defects without apoptosis in the central nervous system. Mol Cell Biol. Feb;23(3):1044-53.

Tsai KY, MacPherson D, Rubinson DA, Nikitin AY, Bronson R, Mercer KL, Crowley D, Jacks T. 2002. ARF mutation accelerates pituitary tumor development in Rb+/- mice. Proc Natl Acad Sci U S A. Dec 24;99(26):16865-70.

Lee HY, Suh YA, Lee JI, Hassan KA, Mao L, Force T, Gilbert BE, Jacks T, Kurie JM. 2002. Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung cancer. Clin Cancer Res. Sep;8(9):2970-5.

Johnson KC, Kissil JL, Fry JL, Jacks T. 2002. Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene. Oncogene. Sep 5;21(39):5990-7.

Klappacher GW, Lunyak VV, Sykes DB, Sawka-Verhelle D, Sage J, Brard G, Ngo SD, Gangadharan D, Jacks T, Kamps MP, Rose DW, Rosenfeld MG, Glass CK. 2002. An induced Ets repressor complex regulates growth arrest during terminal macrophage differentiation.Cell.Apr 19;109(2):169-80.

Yang H, Williams BO, Hinds PW, Shih TS, Jacks T, Bronson RT, Livingston DM. 2002. Tumor suppression by a severely truncated species of retinoblastoma protein.Mol Cell Biol.May;22(9):3103-10.

Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T. 2002. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature.Apr 4;416(6880):560-4.

de Vries A, Flores ER, Miranda B, Hsieh HM, van Oostrom CT, Sage J, Jacks T. 2002. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci U S A. Mar 5;99(5):2948-53.

Kim TJ, Cariappa A, Iacomini J, Tang M, Shih S, Bernards A, Jacks T, Pillai S. 2002. Defective proliferative responses in B lymphocytes and thymocytes that lack neurofibromin.Mol Immunol. Feb;38(9):701-8.

Tsai KY, MacPherson D, Rubinson DA, Crowley D, Jacks T. 2002. ARF is not required for apoptosis in Rb mutant mouse embryos. Curr Biol. 2002 12(2):159-63.

Costa RM, Federov NB, Kogan JH, Murphy GG, Stern J, Ohno M, Kucherlapati R, Jacks T, Silva AJ. 2002. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1.  Nature. 415(6871):526-30.

Kissil JL, Johnson KC, Eckman MS, Jacks T. 2002. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem. Mar 22;277(12):10394-9.

Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15(24):3243-8.

Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I, O'Bryan JP, Gupta V, Ratner N, Der CJ, Jacks T, McClatchey AI. 2001. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell. 1(1):63-72.

Geng Y, Yu Q, Whoriskey W, Dick F, Tsai KY, Ford HL, Biswas DK, Pardee AB, Amati B, Jacks T, Richardson A, Dyson N, Sicinski P. 2001. Expression of cyclins E1 and E2 during mouse development and in neoplasia. Proc Natl Acad Sci U S A.
98(23):13138-43.

Zhang Z, Wang Y, Vikis HG, Johnson L, Liu G, Li J, Anderson MW, Sills RC, Hong HL, Devereux TR, Jacks T, Guan KL, You M. 2001. Wildtype Kras2 can inhibit lung carcinogenesis in mice.  Nat Genet. 29(1):25-33.

Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD.  2001. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.  Oncogene. 16;20(36):5054-8.

Lipinski MM, Macleod KF, Williams BO, Mullaney TL, Crowley D, Jacks T. 2001. Cell-autonomous and non-cell-autonomous functions of the Rb tumor suppressor in developing central nervous system. EMBO J. 2;20(13):3402-13.

Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. 2001. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 410(6832):1111-6.

Sage J, Mulligan GJ, Attardi LD, Miller A, Chen S, Williams B, Theodorou E, Jacks T. 2000. Targeted disruption of the three Rb-related genes leads to loss of G(1) control and  immortalization. Genes Dev.14(23):3037-50.

Wang Y, Hayward SW, Donjacour AA, Young P, Jacks T, Sage J, Dahiya R, Cardiff RD, Day ML, Cunha GR. 2000. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res. 60(21):6008-17.

Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY, Jacks T, Vousden KH, Kaelin WG Jr. 2000. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature. 407(6804):645-8.

Boyd SD, Tsai KY, Jacks T. 2000. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat Cell Biol. 2(9):563-8.

Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. 2000. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet. 26(1):109-13.

Zhang Y, Griffith EC, Sage J, Jacks T, Liu JO. 2000. Cell cycle inhibition by the anti- angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci USA.;97(12):6427-32.

Attardi LD, Reczek EE, Cosmas C, Demicco EG, McCurrach ME, Lowe SW, Jacks T. 2000. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev. 14(6):704-18.

Birnbaum RA, O'Marcaigh A, Wardak Z, Zhang YY, Dranoff G, Jacks T, Clapp DW, Shannon KM. 2000. Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell. 5(1):189-95.

Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, Bronson RT, Jacks T. 1999. Mouse models of tumor development in neurofibromatosis type 1. Science. 286(5447):2172-6.

Mahgoub N, Taylor BR, Gratiot M, Kohl NE, Gibbs JB, Jacks T, Shannon KM. 1999. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. Blood. 94(7):2469-76.

Mahgoub N, Taylor BR, Le Beau MM, Gratiot M, Carlson KM, Atwater SK, Jacks T, Shannon KM. 1999. Myeloid malignancies induced by alkylating agents in Nf1 mice. Blood. 93(11):3617-23.

Zhou X, Wong S, Walter J, Jacks T, Eisen HN. 1999. Increased generation of CD8+ T cell clones in p53 mutant mice. J Immunol. 162(7):3957-60.

Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, Lees JA. 1999. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci U S A. 96(3):1002-7.

Tsai KY, Hu Y, Macleod KF, Crowley D, Yamasaki L, Jacks T. 1998. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol Cell. 2(3):293-304.
 
Xu Y, Yang EM, Brugarolas J, Jacks T, Baltimore D. 1998. Involvement of p53 and p21 in cellular defects and tumorigenesis in Atm-/- mice. Mol Cell Biol. 18(7):4385-90.

Zhang YY, Vik TA, Ryder JW, Srour EF, Jacks T, Shannon K, Clapp DW. 1998. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J Exp Med. 187(11):1893-902.

Zamble DB, Jacks T, Lippard SJ. 1998. p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci U S A. 95(11):6163-8.

McClatchey AI, Saotome I, Mercer K, Crowley D, Gusella JF, Bronson RT, Jacks T. 1998. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 12(8):1121-33.

Shaw RJ, McClatchey AI, Jacks T. 1998. Localization and functional domains of the neurofibromatosis type II tumor suppressor, merlin. Cell Growth Differ. 9(4):287-96.

Shaw RJ, McClatchey AI, Jacks T. 1998. Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. J Biol Chem. 273(13):7757-64.

Brugarolas J, Bronson RT, Jacks T. 1998. p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells. J Cell Biol.Apr 20;141(2):503-14.

Yamasaki L, Bronson R, Williams BO, Dyson NJ, Harlow E, Jacks T. 1998. Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-)mice. Nat Genet. 18(4):360-4.

Nacht M, Jacks T. 1998. V(D)J recombination is not required for the development of lymphoma in p53-deficient mice. Cell Growth Differ.9(2):131-8.

Shaw RJ, Henry M, Solomon F, Jacks T. 1998. RhoA-dependent phosphorylation and relocalization of ERM proteins into apical membrane/actin protrusions in fibroblasts. Mol Biol Cell.Feb;9(2):403-19.

Lanni JS, Jacks T. 1998. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol. 18(2):1055-64.

Mulligan GJ, Wong J, Jacks T. 1998. p130 is dispensable in peripheral T lymphocytes: evidence for functional compensation by p107 and pRB. Mol Cell Biol. 18(1):206-20.

Johnson L, Greenbaum D, Cichowski K, Mercer K, Murphy E, Schmitt E, Bronson RT, Umanoff H, Edelmann W, Kucherlapati R, Jacks T. 1997. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 11(19):2468-81.

Lanni JS, Lowe SW, Licitra EJ, Liu JO, Jacks T. 1997. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci U S A. 94(18):9679-83.

Jones JM, Attardi L, Godley LA, Laucirica R, Medina D, Jacks T, Varmus HE, Donehower LA. 1997. Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Cell Growth Differ. 8(8):829-38.

Montes de Oca Luna R, Amelse LL, Chavez-Reyes A, Evans SC, Brugarolas J, Jacks T, Lozano G. 1997. Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nat Genet. 16(4):336-7.

McClatchey AI, Saotome I, Ramesh V, Gusella JF, Jacks T. 1997. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev. 11(10):1253-65.

van der Geer P, Henkemeyer M, Jacks T, Pawson T. 1997. Aberrant Ras regulation and reduced p190 tyrosine phosphorylation in cells lacking p120-Gap. Mol Cell Biol. 17(4):1840-7.

Silva AJ, Frankland PW, Marowitz Z, Friedman E, Lazlo G, Cioffi D, Jacks T, Bourtchuladze R. 1997. A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat Genet. 15(3):281-4.

Macleod KF, Hu Y, Jacks T. 1996. Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system. EMBO J. 15(22):6178-88.

Novitch BG, Mulligan GJ, Jacks T, Lassar AB. 1996. Skeletal muscle cells lacking the retinoblastoma protein display defects in muscle gene expression and accumulate in S and G2 phases of the cell cycle. J Cell Biol. 135(2):441-56.

Nacht M, Strasser A, Chan YR, Harris AW, Schlissel M, Bronson RT, Jacks T. 1996. Mutations in the p53 and SCID genes cooperate in tumorigenesis. Genes Dev. 10(16):2055-66.

Attardi LD, Lowe SW, Brugarolas J, Jacks T. 1996. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J. 15(14):3693-701.

Cobrinik D, Lee MH, Hannon G, Mulligan G, Bronson RT, Dyson N, Harlow E, Beach D, Weinberg RA, Jacks T. 1996. Shared role of the pRB-related p130 and p107 proteins in limb development. Genes Dev. 10(13):1633-44.

Lee MH, Williams BO, Mulligan G, Mukai S, Bronson RT, Dyson N, Harlow E, Jacks T. 1996. Targeted disruption of p107: functional overlap between p107 and Rb. Genes Dev. 10(13):1621-32.

Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. 1996. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell. 85(4):537-48.

Herrera RE, Sah VP, Williams BO, Makela TP, Weinberg RA, Jacks T. 1996. Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts. Mol Cell Biol. 16(5):2402-7.

Lehar SM, Nacht M, Jacks T, Vater CA, Chittenden T, Guild BC. 1996. Identification and cloning of EI24, a gene induced by p53 in etoposide-treated cells. Oncogene. 12(6):1181-7.

Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K. 1996. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 12(2):144-8.

Tischler AS, Shih TS, Williams BO, Jacks T. 1995. Characterization of Pheochromocytomas in a Mouse Strain with a Targeted Disruptive Mutation of the Neurofibromatosis Gene Nf1. Endocr Pathol.Winter;6(4):323-335.

Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379(6560):88-91.

Henkemeyer M, Rossi DJ, Holmyard DP, Puri MC, Mbamalu G, Harpal K, Shih TS, Jacks T, Pawson T. 1995. Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature. 377(6551):695-701.

Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 377(6549):552-7.

Mombaerts P, Terhorst C, Jacks T, Tonegawa S, Sancho J. 1995. Characterization of immature thymocyte lines derived from T-cell receptor or recombination activating gene 1 and p53 double mutant mice. Proc Natl Acad Sci U S A. 92(16):7420-4.

Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. 1995. A subset of p53-deficient embryos exhibit exencephaly. Nat Genet. 10(2):175-80.

Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T. 1995. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev.9(8):935-44.

Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J, Remington L, Jacks T, Brash DE. 1994. Sunburn and p53 in the onset of skin cancer. Nature. 372(6508):773-6.

Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. 1994.  p53 status and the efficacy of cancer therapy in vivo. Science. 266(5186):807-10.

Strasser A, Harris AW, Jacks T, Cory S. 1994. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell. 79(2):329-39.

Williams BO, Schmitt EM, Remington L, Bronson RT, Albert DM, Weinberg RA, Jacks T. 1994. Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. EMBO J. 13(18):4251-9.

Morgenbesser SD, Williams BO, Jacks T, DePinho RA. 1994. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature. 371(6492):72-4.

Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Van Dyke T. 1994. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 78(4):703-11.

Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T. 1994. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet. 7(4):480-4.

Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. 1994. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet7(3):353-61.

Slebos RJ, Lee MH, Plunkett BS, Kessis TD, Williams BO, Jacks T, Hedrick L, Kastan MB, Cho KR. 1994. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci U S A. 91(12):5320-4.

Lowe SW, Jacks T, Housman DE, Ruley HE. 1994. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci U S A. 91(6):2026-30.

Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. 1994. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 4(1):1-7.

Williams BO, Morgenbesser SD, DePinho RA, Jacks T. 1994. Tumorigenic and developmental effects of combined germ-line mutations in Rb and p53. Cold Spring Harb Symp Quant Biol.59:449-57.

Lowe SW, Bodis S, Bardeesy N, McClatchey A, Remington L, Ruley HE, Fisher DE, Jacks T, Pelletier J, Housman DE. 1994. Apoptosis and the prognostic significance of p53 mutation. Cold Spring Harb Symp Quant Biol. 59:419-26.

Cory S, Strasser A, Jacks T, Corcoran LM, Metz T, Harris AW, Adams JM. 1994. Enhanced cell survival and tumorigenesis. Cold Spring Harb Symp Quant Biol. 59:365-75.

Symonds H, Krall L, Remington L, Saenz Robles M, Jacks T, Van Dyke T. 1994. p53-dependent apoptosis in vivo: impact of p53 inactivation on tumorigenesis. Cold Spring Harb Symp Quant Biol. 59:247-57.

Hatakeyama M, Herrera RA, Makela T, Dowdy SF, Jacks T, Weinberg RA. 1994. The cancer cell and the cell cycle clock. Cold Spring Harb Symp Quant Biol. 59:1-10.

Cobrinik D, Whyte P, Peeper DS, Jacks T, Weinberg RA. 1993. Cell cycle-specific association of E2F with the p130 E1A-binding protein. Genes Dev. 7(12A):2392-404.

Berges RR, Furuya Y, Remington L, English HF, Jacks T, Isaacs JT. 1993. Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci U S A.90(19):8910-4.

Lowe SW, Ruley HE, Jacks T, Housman DE. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74(6):957-67.

Gregory PE, Gutmann DH, Mitchell A, Park S, Boguski M, Jacks T, Wood DL, Jove R, Collins FS. 1993. Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules. Somat Cell Mol Genet. 19(3):265-74.

Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362(6423):847-9.

Chen J, Gorman JR, Stewart V, Williams B, Jacks T, Alt FW. 1993. Generation of normal lymphocyte populations for Rb-deficient ES cells. Curr. Biol. 3(7):405-13.

Corcoran LM, Karvelas M, Nossal GJ, Ye ZS, Jacks T, Baltimore D. 1993. Oct-2, although not required for early B-cell development, is critical for later B-cell maturation and for postnatal survival. Genes Dev. 7(4):570-82.

Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71(4):587-97.

Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. 1992. Effects of an Rb mutation in the mouse. Nature. 359(6393):295-300.

Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. 1992. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell. 70(6):923-35.

Jacks T, Madhani HD, Masiarz FR, Varmus HE. 1988. Signals for ribosomal frameshifting in the Rous sarcoma virus gag-pol region. Cell. 55(3):447-58.

Jacks T, Power MD, Masiarz FR, Luciw PA, Barr PJ, Varmus HE. 1988. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature. 331(6153):280-3.

Jacks T, Townsley K, Varmus HE, Majors J. 1987. Two efficient ribosomal frameshifting events are required for synthesis of mouse mammary tumor virus gag-related polyproteins. Proc Natl Acad Sci U S A. 84(12):4298-302.

Jacks T, Varmus HE. 1985. Expression of the Rous sarcoma virus pol gene by ribosomal frameshifting. Science. 230(4731):1237-42.

Chapters and Reviews

Farago AF, Snyder EL, Jacks T. 2012. SnapShot: Lung cancer models. Cell, 149(1):246-246.e1.

Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG. (2011). Treating metastatic cancer with nanotechnology. Nat Rev Cancer, 12(1):39-50.

Wong KK, Jacks T, Dranoff G. 2010. NF-kappaB fans the flames of lung carcinogenesis. Cancer Prev Res (Phila). 3(4):403-5.

Ventura A and Jacks T. 2009. MicroRNAs and cancer: short RNAs go a long way. Cell, 136(4), 586-591. PMC in progress

Coussens LM, Jacks T. 2008. Genetic and cellular mechanisms of oncogenesis. Curr Opin Genet Dev;18(1):1-2. ePub.

Jacks T.2007. Modeling Cancer in the mouse. Harvey Lect. 2005-2006;101:1-19.

Jacks T.2006. The beginning of the end of frustration. Cold Spring Harb Symp Quant Biol. 2005;70:525-8.

Kim CF, Jackson EL, Kirsch DG, Grimm J, Shaw AT, Lane K, Kissil J, Olive KP, Sweet-Cordero A, Weissleder R, Jacks T..2006. Mouse models of human non-small-cell lung cancer: raising the bar. Cold Spring Harb Symp Quant Biol. 2005;70:241-50.

McLaughlin ME, Jacks T. 2003. Neurofibromatosis type 1.Methods Mol Biol;222:223-37.

McLaughlin ME, Jacks T. 2003. Progesterone receptor expression in neurofibromas.Cancer Res. Feb 15;63(4):752-5.

Jacks T, Weinberg RA.2002. Taking the study of cancer cell survival to a new dimension.Cell. Dec 27;111(7):923-5.

Van Dyke T, Jacks T. 2002.Cancer modeling in the modern era. Progress and challenges. Cell. 108(2):135-44.

Tuveson DA, Jacks T. 2002. Technologically advanced cancer modeling in mice. Curr Opin Genet Dev. 12(1):105-10.

Reilly KM, Jacks T.2001. Genetically engineered mouse models of astrocytoma: GEMs in the rough? Semin Cancer Biol.Jun;11(3):177-91.

DePinho RA, Jacks T.2001. Introduction. The laboratory mouse in cancer research. Semin Cancer Biol. Jun;11(3):175-6.

Cichowski K, Jacks T. 2001. NF1 tumor suppressor gene function: narrowing the GAP.
Cell. Feb 23;104(4):593-604.

Lim DJ, Rubenstein AE, Evans DG, Jacks T, Seizinger BG, Baser ME, Beebe D, Brackmann DE, Chiocca EA, Fehon RG, Giovannini M, Glazer R, Gusella JF, Gutmann DH, Korf B, Lieberman F, Martuza R, McClatchey AI, Parry DM, Pulst SM, Ramesh V, Ramsey WJ, Ratner N, Rutkowski JL, Ruttledge M, Weinstein DE. 2000. Advances in neurofibromatosis 2 (NF2): a workshop report.
J Neurogenet. Jun;14(2):63-106.

Deshaies RJ, Jacks T.1999. Cell multiplication. Peering in and peering out: regulation of and by the cell cycle. Curr Opin Cell Biol. Dec;11(6):705-7.

Lipinski MM, Jacks T. 1999. The retinoblastoma gene family in differentiation and development.
Oncogene. Dec 20;18(55):7873-82.

DePinho RA, Jacks T. 1999. A bumper crop of cancer genes. Nat Genet. Nov;23(3):253-4.

Tuveson DA, Jacks T. 1999. Modeling human lung cancer in mice: similarities and shortcomings. Oncogene.18(38):5318-24.

de Lange T, Jacks T. 1999. For better or worse? Telomerase inhibition and cancer.
Cell. Aug 6;98(3):273-5.

Attardi LD, Jacks T. 1999. The role of p53 in tumour suppression: lessons from mouse models.
Cell Mol Life Sci. Jan;55(1):48-63.

Macleod KF, Jacks T. 1999. Insights into cancer from transgenic mouse models.
J Pathol. Jan;187(1):43-60.

McClatchey AI, Jacks T. 1998. Tumor suppressor mutations in mice: the next generation. Curr Opin Genet Dev. 8(3):304-10. Review.

Mulligan G, Jacks T. 1998. The retinoblastoma gene family: cousins with overlapping interests.
Trends Genet. Jun;14(6):223-9.

Jacks T, Weinberg RA. 1998. The expanding role of cell cycle regulators.
Science. May 15;280(5366):1035-6.

Cichowski K. Jacks T. 1998. Animal models of neurofibromatosis type 1. In Neurofibromatosis Type 1, From Genotype to Phenotype, Vol 12. Oxford: BIOS Scientific Publishers Limited, pp 191-201.

Macleod K, Jacks T. 1997. The retinoblastoma gene and the control of apoptosis. In Apoptosis and Cancer, Vol 8. London: Macmillan, pp 141-64.

Brugarolas J, Jacks T. 1997. Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. Nat Med. Jul;3(7):721-2.

Collins K, Jacks T, Pavletich NP. 1997. The cell cycle and cancer. Proc Natl Acad Sci U S A. Apr 1;94(7):2776-8.

Cichowski K, Shih TS, Jacks T. 1996. Nf1 gene targeting: toward models and mechanisms. Semin Cancer Biol. 7(5):291-8. Review.

Jacks T. 1996. Tumor suppressor gene mutations in mice. Annu Rev Genet. 30:603-36.

Jacks T. 1996. Lessons from the p53 mutant mouse. J Cancer Res Clin Oncol. 122(6):319-27.

Jacks T, Weinberg RA. 1996. Cell-cycle control and its watchman. Nature. Jun 20;381(6584):643-4.

Williams BO, Jacks T. 1996. Mechanisms of carcinogenesis and the mutant mouse. Curr Opin Genet Dev. Feb;6(1):65-70.

Cory S, Strasser A, Jacks T, Corcoran LM, Metz T, Harris AW, Adams JM. 1994. Enhanced cell survival and tumorigenesis. Cold Spring Harb Symp Quant Biol. 59:365-75.

Williams BO, Morgenbesser SD, DePinho RA, Jacks T. 1994. Tumorigenic and developmental effects of combined germ-line mutations in Rb and p53. Cold Spring Harb Symp Quant Biol. 59:449-57.

Symonds H, Krall L, Remington L, Saenz Robles M, Jacks T, Van Dyke T. 1994. p53-dependent apoptosis in vivo: impact of p53 inactivation on tumorigenesis. Cold Spring Harb Symp Quant Biol. 59:247-57.

Lowe SW, Bodis S, Bardeesy N, McClatchey A, Remington L, Ruley HE, Fisher DE, Jacks T, Pelletier J, Housman DE. 1994. Apoptosis and the prognostic significance of p53 mutation. Cold Spring Harb Symp Quant Biol. 59:419-26.

Riccardi VM, Womack JE, Jacks T. 1994. Neurofibromatosis and related tumors. Natural occurrence and animal models. Am J Pathol. 145(5):994-1000. Review.

Hatakeyama M, Herrera RA, Makela T, Dowdy SF, Jacks T, Weinberg RA. 1994. The cancer cell and the cell cycle clock. Cold Spring Harb Symp Quant Biol. 59:1-10.

Jacks T. 1990. Translational suppression in gene expression in retroviruses and retrotransposons. Curr Top Microbiol Immunol. 157:93-124. Review.

Madhani H, Jacks T, Varmus HE. 1998. Signals for the expression of the HIV pol gene by ribosomal frameshifting. In The Control of Human Retrovirus Gene Expression. New York: Cold Spring Harbor Press, pp 119-25.